Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis
- PMID: 40251607
- PMCID: PMC12008916
- DOI: 10.1186/s12978-025-02004-2
Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis
Abstract
Background: Chikungunya virus significantly impacts public health, primarily affecting regions in Africa and the Americas (predominantly Latin America and the Caribbean). Despite the global spread of the virus and its clinical manifestations and complications in vulnerable populations such as children and pregnant persons, no widely available vaccine is currently available. With recent advancements in vaccine development, there is a need to systematically evaluate the emerging evidence on the safety, immunogenicity, and efficacy of chikungunya vaccine candidates. This protocol outlines a living systematic review designed to continuously assess the growing research on chikungunya vaccines, focusing on diverse populations, including children and pregnant persons. We aim to provide up-to-date evidence to inform public health decisions and vaccine recommendations as new data is available.
Methods: Our objective is to carry out a living systematic review and meta-analysis through biweekly searches in medical databases and clinical trial registries, aiming to identify relevant chikungunya vaccines studies on pregnant individuals, children, and adolescents. Pairs of reviewers will independently screen studies, extract data, and assess the risk of bias. Clinical trials, quasi-experimental studies, and observational studies, including case reports, will be considered for inclusion. Main outcomes will include the safety, efficacy, and effectiveness of chikungunya vaccines in pregnant individuals (including neonatal outcomes), as well as in children and adolescents. Reactogenicity and immunogenicity will be considered as secondary outcomes. Paired meta-analyses, incorporating predefined subgroup and sensitivity analyses, will be performed. Evidence certainty will be assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
Discussion: This living systematic review and meta-analysis will continuously assess the safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents. Given the significant disease burden and potential complications in these populations, synthesizing emerging evidence is crucial for guiding immunization policies and clinical recommendations. By maintaining an updated analysis, this review will provide timely insights for public health agencies, researchers, and clinicians involved in vaccine implementation and maternal-child health.
Study registration: Two protocols were registered in the International Prospective Register of Systematic Reviews database, CRD42024514513 and CRD42024516754.
Keywords: Chikungunya; Children, Protocol, Systematic review; Meta-analyses; Pregnancy; Vaccine.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics and dissemination: Ethical approval is not required for this study, given that this is a protocol for a systematic review and meta-analysis using published data. The systematic review and living meta-analysis results will be widely disseminated via the online dashboards described above. One or more summary papers will be submitted to a leading peer-reviewed journal in this field, adhering to the PRISMA statement/extension for reporting LSR. (56). Consent for publication: Not applicable. This study does not involve individual patient data or identifiable personal information requiring consent for publication. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.
Similar articles
-
Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis.Reprod Health. 2025 Apr 15;22(1):53. doi: 10.1186/s12978-025-02008-y. Reprod Health. 2025. PMID: 40234991 Free PMC article.
-
Safety, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons: A protocol for systematic review and meta analysis.Medicine (Baltimore). 2023 Mar 3;102(9):e32954. doi: 10.1097/MD.0000000000032954. Medicine (Baltimore). 2023. PMID: 36862871 Free PMC article.
-
Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.Hum Vaccin Immunother. 2025 Dec;21(1):2463191. doi: 10.1080/21645515.2025.2463191. Epub 2025 Feb 11. Hum Vaccin Immunother. 2025. PMID: 39932481 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials.J Gen Virol. 2024 Feb;105(2). doi: 10.1099/jgv.0.001965. J Gen Virol. 2024. PMID: 38421278 Review.
Cited by
-
A global living systematic review and meta-analysis hub of emerging vaccines in pregnancy and childhood.Reprod Health. 2025 Jul 18;22(1):129. doi: 10.1186/s12978-025-02090-2. Reprod Health. 2025. PMID: 40682141 Free PMC article.
References
-
- Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017;17(4):e107–17. - PubMed
-
- Expansión geográfica de los casos de dengue y chikungunya más allá de las áreas históricas de transmisión en la Región de las Américas [Internet]. [cited 2025 Feb 5]. Available from: https://www.who.int/es/emergencies/disease-outbreak-news/item/2023-DON448
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical